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Abstract: The role of calcification in coronary artery disease is gaining importance, both in 
research studies and in clinical application. Calcified plaque has long been considered to be the 
most important atherosclerotic plaque within the arterial tree and frequently presents a challenge 
for percutaneous intervention. Current investigations have shown that plaque calcification has 
a dynamic course that is closely related to the magnitude of vascular inflammation. Numerous 
inflammatory factors synthesized during the early stages of atherosclerosis induce the expres-
sion and activation of osteoblast-like cells localized in the arterial wall that produce calcium. 
There is no doubt that the role of these factors in calcification associated with coronary artery 
disease could be a crucial strategic point in prevention and treatment. A number of diagnostic 
imaging methods have been developed in recent years, but their performance needs to be 
improved. In this context, we undertook an update on coronary calcification, focusing on 
  physiopathology, clinical implications, and imaging techniques.
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Introduction
The role of “skeletonization”, referred to as calcification, in the development of coronary 
artery disease is gaining importance, both in research and in clinical application.   Calcified 
plaque has long been recognized as the most important atherosclerotic plaque within the 
arterial tree,1 and frequently presents a challenge for percutaneous intervention.2 Current 
investigations have shown that plaque calcification has a dynamic course that is closely 
related to the magnitude of vascular inflammation.3 Numerous inflammatory factors 
synthesized during the early stages of atherosclerosis induce the expression and activa-
tion of osteoblast-like cells localized in the arterial wall that produce calcium.4,5
In approximately 15% of human atherosclerotic plaques, calcium precipitation 
develops a complete skeletal architecture, histologically indistinguishable from 
  trabecular bone, even including marrow and cartilage.6
It is now understood that microcalcification deposits in the borders of atherosclerotic 
plaque are related to increased risk for plaque instability and fibrous cap rupture, 
  followed by coronary thrombus formation and adverse clinical events.7 Thus, the 
perception that calcified plaques are less vulnerable to rupture has been adapted in 
order to investigate the characteristics of calcification, such as extent, location, and 
morphology.7
Calcium deposits may be found at many sites in the cardiovascular tree, including 
in the medial layer of the large arteries (medial arterial calcification), within athero-
sclerotic plaque (intimal calcification), on cardiac valves, particularly mitral and aortic, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and in the microvessels (calcific uremic arteriolopathy).8 
Calcium deposition at these different sites follows different 
clinical courses, and they each seem to have at least some 
distinct pathophysiologic features.
Osteogenic induction
Vascular smooth muscle cells have an extraordinary capacity 
to undergo phenotypic differentiation. This depends on 
media status, injury factors, and their influence on specific 
transcription factors. Such phenotypic changes may be very 
important in the pathological process, and might even be their 
key factor.9
Cbfa1, Msx2, and Sox9 are identified as the master 
  regulators of bone and cartilage differentiation.10–12 These 
are responsible for the regulation of several genes related to 
osteocytic/chondrocytic differentiation in vascular smooth 
muscle cells. Tyson et al13 could not detect expression of 
these regulatory factors in freshly dispersed normal vascular 
smooth muscle cells by reverse transcription polymerase 
chain reaction. However, in vitro, phenotypically modified 
calcifying vascular smooth muscle cells activate different 
transcriptional pathways, associated with variation in expres-
sion of these master regulators and their target genes.13
Several stimuli may induce vascular smooth muscle 
cells to undergo osteogenic differentiation. Oxidative stress, 
  defective phosphate and calcium production, and lack of 
calcification inhibitors, among other factors, will be discussed 
in order to explain osteogenic induction.13
Agonists of the osteochondrogenic 
phenotype
Byon et al14 demonstrated the very important role of oxidative 
stress in osteogenic differentiation in vascular smooth 
muscle cells. H2O2 promotes the specific phenotypic change 
associated with increased expression and transactivity of 
Runx2, a key transcription factor for osteogenic differentiation. 
Real-time polymerase chain reaction performed in H2O2-
treated cultures showed a significant increase in the expres-
sion of bone markers, whereas the expression of vascular 
smooth muscle cell markers decreased gradually during 
osteogenic differentiation of vascular smooth muscle cells 
undergoing H2O2 treatment.14
Lipoproteins, like native low-density lipoprotein and 
acetylated low-density lipoprotein, influence the expression 
of a subset of bone marker genes, like alkaline phosphatase 
and bone sialoprotein, in vascular smooth muscle cells 
in vitro and have an important role in vascular calcification. 
Proudfoot et al15 demonstrated this in a model of vascular 
smooth muscle cell calcification in which postconfluent 
vascular smooth muscle cells formed nodules that calcified 
within 28 days.15
Loss of inhibition
Fetuin-A, also known as (alpha2)-Heremens-Schmid glyco-
protein, is a protein made in the liver and secreted into the 
blood stream. It belongs to a large group of binding proteins 
mediating the transport and availability of a wide variety of 
cargo substances in the blood. Reynolds et al16 demonstrated 
that mice lacking fetuin-A exhibit extensive soft tissue 
  calcification, suggesting that fetuin-A inhibits calcification 
systemically. Uptake of fetuin-A by vascular smooth muscle 
cells is a key event in the inhibition of vesicle-mediated 
vascular smooth muscle cell calcification. Fetuin-A is barely 
detectable in the media or intima of noncalcified normal 
arteries by immunohistochemistry. However, fetuin-A stain-
ing is present in calcified medial and intimal areas of arteries, 
both deposited in association with vascular smooth muscle 
cells and the matrix. Vascular smooth muscle cells within 
calcified regions are strongly positive for fetuin-A. Reverse 
transcription polymerase chain reaction in normal and calci-
fied arteries cannot detect fetuin-A mRNA, indicating that 
it is not synthesized by vascular smooth muscle cells, but 
derived from the serum. Fetuin-A inhibits vascular smooth 
muscle cell calcification induced by media containing   calcium 
and phosphate ions. Fetuin-A is a binder of basic calcium 
phosphate and an inhibitor of spontaneous precipitation of 
calcium and phosphate in solution. In the presence of vascular 
smooth muscle cells, the inhibitory capacity of fetuin-A is 
significantly increased, suggesting that it also acts via cell-
mediated mechanisms.16 Apoptosis contributes to vascular 
smooth muscle cell calcification induced by calcium and 
phosphate ions in serum-free conditions. Immunofluorescent 
TUNEL labeling shows that apoptosis induced in response 
to medium containing calcium and phosphate ions was 
  significantly reduced by 5 µM fetuin-A. Fetuin-A reduces 
apoptotic events by approximately half over a 48-hour time 
course, and this is associated with reduced cleavage of 
  caspases 3, 8, and 9. Matrix vesicles that are released 
from vascular smooth muscle cells cultured in the presence 
of fetuin-A do not calcify. In contrast, matrix vesicles 
released from vascular smooth muscle cells in the absence 
of fetuin-A calcify extensively. Fetuin-A is taken up by 
vascular smooth muscle cells and loaded into intracellular 
vesicles, where it prevents nucleation of basic calcium 
  phosphate. It also enhances the potential for apoptotic body 
clearance and limits their capacity to bind and nucleate basic Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
145
Skeletonized coronary arteries
calcium phosphate in the extracellular matrix. The potential 
role of fetuin-A in regulating the osteoblastic phenotype of 
vascular smooth muscle cells should be investigated.16
Additional factors that modulate 
bone formation
Reactive oxygen species
The contribution of oxidative stress and vascular calcification 
may provide a link between inflammation and vascular 
  calcification, which are both conditions present in athero-
sclerotic plaque. Interestingly, calcific vasculopathy may be 
a compensatory response to the chronic inflammation of 
atherosclerosis, because it occurs in calcification surrounding 
tuberculoma, carcinomas, helminthic infections, or foreign 
body inclusions.17
Reactive oxygen species signaling can induce markers 
of osteoblastic differentiation, including bone morpho-
genic protein-2 (BMP2) and Cbfa1. Under oxidative stress 
  conditions, certain subpopulations of cardiovascular cells can 
develop a capacity for osteogenesis. Endothelial cells, when 
exposed to oxidized low-density lipoprotein, express BMP2.18 
BMP2 induces cyclo-oxygenase-2 mRNA expression and 
prostaglandin production in cultured osteoblasts.19 In addition, 
in endothelial cells, BMP2 increases expression of nicotin-
amide adenine dinucleotide phosphate oxidase, thereby 
increasing superoxide formation. In addition, BMP2 in the 
endothelium induces intercellular adhesion molecule-1 
expression, facilitating the adhesive interactions with circu-
lating monocytes.19
Alkaline phosphatase
Alkaline phosphatase, a functional phenotype marker of 
osteoblasts, modulates vascular calcification by decreasing 
levels of inorganic pyrophosphate.20 Pyrophosphate is a 
potent inhibitor of calcification, particularly in vessel walls. 
Alkaline phosphatase activity is often used as a molecular 
marker for osteogenic and chondrogenic differentiation. 
Accordingly, smooth muscle cells undergoing medial calci-
fication express higher levels of alkaline phosphatase, and 
the classic stimuli of atherosclerotic vascular calcification, 
including BMP2 and oxidized low-density lipoprotein, 
increase alkaline phosphatase activity in cultured vascular 
smooth muscle cells.21
Leptin
Serum leptin levels may contribute to vascular calcification. 
Leptin levels are associated with both visceral obesity and 
renal failure (as a consequence of reduced leptin filtration).22 
In addition, there is evidence that leptin may selectively 
modulate vascular smooth muscle cells to undergo osteo-
blastic differentiation.23 In aortic endothelial cells, leptin 
increases oxidative stress, which has been shown to increases 
BMP2 production by these cells.24
Apoptosis
Exaggerated apoptosis of vascular smooth muscle cells 
occurs in several pathological conditions and as a normal 
consequence of aging. Apoptotic bodies of dead foam cells 
and smooth muscle cell debris, in addition to matrix vesicles 
derived from viable smooth muscle cells and calcific vascular 
cells, may serve to concentrate calcium and phosphate locally.25 
Apoptosis, in part, can explain the medial calcification com-
mon in the elderly.
Coronary artery calcification  
in end-stage renal disease
Cardiovascular disease is the primary cause of mortality among 
adults with chronic renal disease, with a 10–20-fold higher 
mortality rate compared with the general population without 
renal function impairment.26 It has become apparent that vas-
cular calcification is a strong prognostic marker of cardiovas-
cular disease mortality in patients with chronic renal disease,27,28 
even amongst children with end-stage kidney disease.29
The pathogenesis of vascular calcification in chronic renal 
disease is not well understood. Vascular calcification has 
long been considered to be a passive, degenerative, and end-
stage process of atherosclerosis and inflammation. At the 
present time, numerous factors have been identified to par-
ticipate in the formation of vascular calcification in chronic 
renal disease.30 In patients with chronic renal disease, several 
studies have found associations between both traditional risk 
factors, such as hypertension, hyperlipidemia, and diabetes, 
and uremic-specific risk factors for vascular calcification. 
These latter factors consist of hyperphosphatemia and 
  calcium-regulating hormones.30
Most patients with progressive chronic renal disease 
develop hyperphosphatemia, which mediates matrix miner-
alization in vascular smooth muscle cells.31 Elevated phos-
phate may directly stimulate smooth muscle cells to undergo 
phenotypic changes that predispose to calcification.32
Contemporary understanding suggests that bone matrix 
proteins such as osteopontin, matrix Gla protein, and 
  osteocalcin are expressed in calcified atherosclerotic lesions, 
and that calcium-regulating hormones, such as vitamin D3 
and parathyroid hormone-related protein, regulate vascular 
  calcification in in vitro vascular calcification models based Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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on cultured aortic smooth muscle cells. These findings   suggest 
that vascular calcification is an actively regulated process 
similar to osteogenesis, and that bone-associated proteins may 
be involved in the development of vascular calcification.32
Calcitriol is indicated in patients with chronic renal dis-
ease in order to avoid secondary hyperparathyroidism related 
to impaired ability of the ailing kidney to convert vitamin D 
into its active form, 1,25(OH)2D3. Calcitriol elevates serum 
calcium levels and inhibits parathyroid hormone secretion. 
However, although this therapy aims to prevent secondary 
hyperparathyroidism, the consequent increase in serum 
calcium levels, together with increased serum phosphate, 
may inadvertently induce mineralization in the vasculature. 
Therefore, the recommendation for vitamin D intake must be 
made with caution due to its role in vascular calcification.32
Role of high-density lipoprotein  
in vascular calcification
High-density lipoprotein may inhibit vascular calcification 
by modulating the osteogenic activity of calcifying vascu-
lar cells. Parhami et al33 treated calcifying vascular cells with 
high-density lipoprotein and noted that alkaline phosphatase 
activity, a marker of osteogenic differentiation of osteoblastic 
cells, was markedly affected in those cells. In addition, chronic 
treatment with high-density lipoprotein also inhibited calci-
fication of the cells. Furthermore, high-density lipoprotein 
inhibited the osteogenic activity induced by the inflammatory 
cytokines, interleukin-1 and interleukin-6, as did minimally 
oxidized low-density lipoprotein33 (see Figures 1 and 2).
Categories of vascular calcification
Categories of cardiovascular calcification have been identi-
fied clinically, ie, atherosclerotic or intimal calcification, 
medial artery calcification, vascular calciphylaxis, and 
  cardiac valve calcification.34 Vascular calcification occurs 
in both the intimal and the medial layers of the arteries. 
  However, there is evidence to suggest that these two sites of 
calcification are distinct entities, but can occur simultane-
ously and synergistically aggravate artery burden.34
Atherosclerotic calcification
Intimal calcification only occurs within atherosclerotic 
plaques, and is seen as early as the second decade of life, 
just after the fatty streak is formed.35 This stage of cellular 
events is characterized by oxidation of low-density lipo-
protein cholesterol, recruitment of T cells, and activation of 
  macrophages. The process of “skeletonization” is initially 
developed through endochondrial ossification which, 
in turn, precedes osteoblast induction and lamellar bone 
  formation. As the lesion progresses, osteogenesis is apparent 
and is occasionally quite complex, inclusively with marrow 
  formation.36 Importantly, bone-related proteins are present 
as early as the intimal xanthoma stage of lesion progression, 
and histological   evidence of calcification is visible once a 
lipid core is outlined.37
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Figure  1  effect  of  high-density  lipoprotein  on  cardiovascular  cell  responses  to 
interleukin-1. A) Cardiovascular cell cultures were pretreated for 24 hours with high-
density lipoprotein (200 µg/mL) in Dulbecco’s Modified Eagle Medium containing 5% 
fetal bovine serum, followed by the addition of fresh high-density lipoprotein with or 
without interleukin-1 (10 ng/mL). After two days, alkaline phosphatase activity was 
measured as previously described. Results from a representative of three experiments 
are shown as mean ± standard deviation of quadruple determinations. P , 0.005 for 
untreated  control  versus  interleukin-1-treated  samples,  for  interleukin-1-  versus 
interleukin-1 + high-density lipoprotein-treated samples, and for untreated control 
versus high-density lipoprotein-treated samples. B) Cells were treated as described 
above. After 10 days, a  45Ca incorporation assay was performed. Results from a 
representative of three experiments are shown as mean ± standard deviation of 
quadruple determinations. P , 0.005 for untreated control versus interleukin-1-
treated samples and for interleukin-1- versus interleukin-1 + high-density lipoprotein-
treated samples. Adapted from Parhami et al.33Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The role of calcification in the process of atherosclerotic 
plaque rupture is unclear. Research studies have demon-
strated that plaque may rupture due to physical stress exerted 
at sites of calcification on the fibrous cap and is biphasic and 
dose-dependent, based on mechanical stress considerations. 
Plaque calcification initially destabilizes a plaque, specifi-
cally at the areas of interface between hard and soft tissues.38 
As the degree of calcification increases, the number of 
  interfaces between rigid and distensible plaque initially would 
increase until the point at which the rigid plaques coalesce 
(Figure 3). Further calcification would result in a decreased 
interface area and reducing the chances of rupture.39 On the 
other hand, other investigations have suggested that calcified 
plaques are more stable and less prone to rupture.40
In addition, focal calcification strongly favors arterial 
dissection during coronary interventions, such as angioplasty 
and stent placement.41 Angioplasty to extensively calcified 
lesions in particular carries an increased risk, even in the 
stent and glycoprotein IIb/IIIa era, because of higher failure 
and complication rates. Calcified lesions are stiff and resistant 
to adequate dilatation, leading to increased risk of vessel 
closure from dissections originating at the junction of the 
calcified and noncalcified regions of the plaque. In addition, 
the high inflation pressures required increase the risk of bal-
loon rupture and even vessel perforation. Rotational atherec-
tomy has been shown to increase success and to reduce the 
complication rate in calcified lesions, but the restenosis rate 
remains unchanged.42
Stenting of highly calcified lesions is also problematic 
because of lack of full stent expansion and difficulty in deliv-
ery to the target site. Several studies have shown improved 
results by using rotational atherectomy to debulk the calcium 
before stent placement. These studies showed appropriate 
stent expansion in most cases, and a reduced restenosis 
rate compared with rotational atherectomy   followed by 
angioplasty alone.43
Medial artery calcification
On the other hand, medial calcification occurs independently 
of intimal calcification and atherosclerosis. Metabolic dis-
orders, such as uremia, hyperparathyroidism, and diabetes, 
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Figure  2  effect  of  high-density  lipoprotein  on  cardiovascular  cell  responses  to 
interleukin-6. A) Cardiovascular cell cultures were pretreated for 24 hours with   
high-density lipoprotein (200 µg/mL) in Dulbecco’s Modified Eagle Medium containing 
5% fetal bovine serum, followed by the addition of fresh high-density lipoprotein with 
or without interleukin-6 (50 ng/mL). After four days, alkaline phosphatase activity 
was  measured  as  previously  described.  Results  from  a  representative  of  three 
experiments are shown as mean ± standard deviation of quadruple determinations. 
P , 0.001 for control versus interleukin-6-treated samples and for interleukin-6- 
versus interleukin-6 + high-density lipoprotein-treated samples; P , 0.05 for control 
versus high-density lipoprotein-treated samples. B) Cells were treated as described 
above. After 10 days, a 45Ca incorporation assay was performed. Results from three 
representative experiments are shown as mean ± standard deviation of quadruple 
determinations.  P  ,  0.001  for  control  versus  interleukin-6-treated  samples  and 
for interleukin-6- versus interleukin-6 + high-density lipoprotein-treated samples. 
Adapted from Parhami et al.33
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Figure 3 Relationship between plaque interface area versus total calcium mass. 
Biomechanical principles suggest the risk of plaque rupture should correlate with 
the interface area, which eventually decreases as calcified plaques begin to coalesce. 
The corresponding figure insets illustrate how the interface (the circumference around 
the black area) eventually decreases as calcified areas continue to form and grow. 
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are associated with development of medial calcification that 
occurs even in areas without adjacent atherosclerosis.44
Medial calcification is more likely to be present in the 
peripheral arteries of the lower limbs in otherwise healthy 
elderly patients (Monckeberg’s sclerosis), where it is seen as 
“rail tracking” on plain radiographs. However, it also occurs 
in younger patients with diabetes and in patients with chronic 
renal failure. In diabetic patients, medial calcification appears 
to be a strong independent predictor of cardiovascular mor-
tality and occurs particularly in those with neuropathy.44 
Specifically within diabetic patients, medial calcification is 
a result of migration of procontractile adventitial myofibro-
blasts into the medial layer and, subsequently, transformation 
to an osteoblastic phenotype when vascular cell smooth 
muscle cells express osteopontin.44
In terms of clinical importance, medial calcification is a 
risk factor for arterial stiffness. This phenomenon results 
in difficulties in palpating pulses and hearing Korotkoff 
sounds, leading to false elevation of systolic blood pressure 
measurements.44 Another complication related to vascular 
stiffness is the onset of left ventricular hypertrophy (due to 
increases in pulse-wave velocity and systolic blood pressure, 
and to a decrease in diastolic blood pressure).45 It also causes 
problems with the surgical management of vascular shunts. 
Further investigations are necessary to distinguish between 
superficial, focal atherosclerotic calcification and deep, 
concentric medial calcification and risk of plaque rupture.
Calciphylaxis
A very rare phenomenon, vascular calciphylaxis, or calcific 
uremic arteriolopathy, occurs in approximately 1% of patients 
on hemodialysis. This vascular condition is a systemic process 
involving diffuse calcification of the media of small-sized to 
medium-sized arteries and arterioles with intimal proliferation 
leading to tissue necrosis, such as in skin, muscle, and fat.46
Calciphylaxis is not dependent on active osteogenesis 
and, in patients with chronic renal disease or secondary 
hyperparathyroidism, can be preceded by either extensive 
use of warfarin or by significant weight loss. It has also 
been related to immunosuppressive agents, diabetes, obesity, 
and hypercoagulable states. Calciphylaxis has a mortality 
rate of 60%–80%.46
Imaging techniques to visualize 
coronary “skeletonization”
A diversity of imaging modalities is accessible to detect 
arterial calcification, including roentgenography, echocar-
diography, intravascular ultrasound, and computerized 
tomography. These modalities differ both in sensitivity and 
specificity, as well as clinical relevance.46
Chest roentgenography and 
echocardiography
Chest radiography is a weak tool for detecting vascular 
calcification. Widespread, extensive calcification can be 
visualized through radiograms in the aorta, which could 
suggest concomitant coronary damage. A similar rationale 
also occurs with the use of echocardiography where valvular 
calcification can be easily diagnosed (Figure 4).46
intravascular ultrasound
This modality serves to identify sites of calcification within 
the different components of the artery wall (intima, media 
and adventitia) and within plaques. Intravascular ultrasound 
has both high specificity and sensitivity for calcified areas, 
as it appears hyperechoic (Figure 5).47 A drawback of intra-
vascular ultrasound is the fact that it is an invasive, nonquan-
titative procedure and visualizes only a limited portion of 
the coronary artery circulation. However, it is a very useful 
instrument for the interventional cardiologist because it can 
identify areas with localized calcification, specifically those 
areas at risk for dissection.48,49
Computed tomography
Necropsy studies have demonstrated that the amount of 
intimal calcium in the coronary arteries is related closely to 
the amount of plaque. In other words, where there is calcifi-
cation there is usually plaque, and where there is plaque there 
is usually calcification.50 Computed tomography (CT) has 
become known as a noninvasive, sensitive method to detect 
and measure coronary calcification and stenosis. Two major 
CT methods used to evaluate and assess plaque burden, 
Figure 4 Echocardiography image showing calcified aortic valve.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Skeletonized coronary arteries
composition, and extension, mainly regarding coronary heart 
disease will be discussed, ie, CT coronary angiography and 
the use of the standardized Agatston scoring system in order 
to create coronary artery calcium scores. Using coronary 
artery calcium scores, CT imaging permits quantification of 
artery calcification (Figure 6).51,52 Many studies have com-
pared information on CT and coronary artery calcium scores, 
and most of them have concluded that information from 
each of these examinations is very helpful to the other.53 
Coronary artery calcium scoring is considered to improve 
the prediction of the presence of obstructive coronary artery 
disease independent of clinical predictors.54 Meantime, 
multislice CT coronary angiography has been shown to 
provide additional information regarding stenosis severity 
and plaque composition, which translates into incremental 
prognostic value over coronary artery calcium scores.55 
Furthermore, an interesting study compared evaluation of 
the atheroma burden with CT coronary angiography and 
coronary artery calcium scores in patients at significant risk 
for coronary artery disease, such as age and diabetes. The 
conclusion was that CT coronary angiography was superior 
in determining the atheroma burden in this group of patients.56 
Despite the comparison between CT coronary angiography 
and coronary artery calcium scoring, an increasing amount 
of evidence has consistently shown increased coronary artery 
calcium scores to be positively correlated with atherosclerotic 
plaque burden.57 In diabetic patients, coronary artery calcium 
scoring may be a useful follow-up examination once it has 
been demonstrated that every increase in coronary artery 
calcium score is strongly correlated with a greater increase 
in mortality.58 The coronary artery calcium score may be a 
complementary risk factor to traditional cardiovascular 
stratification factors.59 A positive correlation between coro-
nary calcium score and subsequent clinical events in patients 
with known coronary artery disease has been documented.57 
On the other hand, a coronary artery calcium score of zero 
has a negative predictive value of about 95% for important 
epicardial coronary artery stenosis.60 As a screening tool for 
obstructive coronary artery disease, coronary artery calcium 
scoring is not recommended for low-risk populations due 
to its low specificity and a high false positive rate, although 
its selective use in patients at intermediate risk may be 
appropriate.61
Conclusion
There is no doubt that the role of calcification in coronary 
artery disease could be a crucial strategic point in prevention 
and treatment. However, we are only at the beginning of our 
understanding of this topic, and so many studies are neces-
sary to clarify the complete physiopathology and perhaps 
help in prevention. Different diagnostic imaging methods 
Figure  5  intravascular  ultrasound  image  showing  necrotic  core  in  a  thin-cap 
fibroatheroma lesion appearing as red (top) and dense calcium in fibrocalcific disease 
appearing as white (bottom). Adapted from Murray et al.49  
Figure 6 Computed tomographic image showing coronary calcification not shown 
in the same lesion on coronary angiography. Adapted from Mittal et al.52Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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have been developed in recent years, but their performance 
needs to be improved.
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